Información de Regeneron Pharmaceuticals Inc, dividendo de Regeneron Pharmaceuticals Inc, actividades de los accionistas y más

Más Datos de Regeneron Pharmaceuticals Inc Compañía

Regeneron Pharmaceuticals, Inc. is a fully integrated biotechnology company. The Company invents, develops, manufactures, and commercializes medicines for people with serious diseases. Its products and product candidates in development are designed to help patients with eye diseases, allergic and inflammatory diseases, cancer, cardiovascular and metabolic diseases, neurological diseases, hematologic conditions, infectious diseases, and rare diseases. The Company helps in accelerating and improving the traditional drug development process through its VelociSuite technologies, such as VelocImmune, which uses genetically humanized mice to produce optimized fully human antibodies and bispecific antibodies, and through ambitious research initiatives such as the Regeneron Genetics Center. Its marketed products include EYLEA (aflibercept) Injection; Dupixent (dupilumab) Injection; Libtayo (cemiplimab) Injection; Praluent (alirocumab) Injection; Kevzara (sarilumab) Injection, and others.

Información de Regeneron Pharmaceuticals Inc



Símbolo de cotizaciónREGN

Nombre de la empresaRegeneron Pharmaceuticals Inc

Fecha de salida a bolsaApr 02, 1991

Director ejecutivoDr. Leonard S. Schleifer, M.D., Ph.D

Número de empleados15106

Tipo de seguridadOrdinary Share

Fin del año fiscalApr 02

Dirección777 Old Saw Mill River Road

CiudadTARRYTOWN

Bolsa de valoresNASDAQ Global Select Consolidated

PaísUnited States of America

Código postal10591

Teléfono17813705000

Sitio Webhttps://www.regeneron.com/

Símbolo de cotizaciónREGN

Fecha de salida a bolsaApr 02, 1991

Director ejecutivoDr. Leonard S. Schleifer, M.D., Ph.D

Ejecutivos de Regeneron Pharmaceuticals Inc



Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

54.39K

+1.82%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Mr. Christopher R. Fenimore

Chief Financial Officer, Executive Vice President - Finance

19.75K

+20.78%

Mr. Arthur F. (Art) Ryan

Independent Director

17.66K

-0.10%

Ms. Marion E. McCourt

Executive Vice President - Commercial

14.37K

+9.94%

Dr. Michael S. Brown, M.D.

Independent Director

12.62K

-0.13%

Nombre

Nombre/Posición

Posición

Accionistas

Cambio

Dr. George D. Yancopoulos, M.D., Ph.D

Co-Chairman of the Board, President, Chief Scientific Officer

1.11M

+42.02%

Dr. Leonard S. Schleifer, M.D., Ph.D

Co-Chairman of the Board, President, Chief Executive Officer, Founder

670.48K

-3.59%

Dr. Andrew J. Murphy, Ph.D.

Executive Vice President - Research

54.39K

+1.82%

Mr. Joseph J. LaRosa

Executive Vice President, General Counsel, Secretary

42.00K

+2.78%

Mr. Daniel P. Van Plew

Executive Vice President, General Manager - Industrial Operations and Product Supply

35.92K

+0.07%

Mr. George L. Sing

Independent Director

29.89K

-0.06%

Desglose de ingresos

Divisa: USDActualizado: lun., 6 de oct

FY2025Q2

FY2025Q1

FY2024

FY2024Q4

FY2024Q3

FY2024Q2

FY2024Q1

FY2023

FY2023Q4

FY2023Q3

FY2023Q2

FY2023Q1

FY2022

FY2022Q4

FY2022Q3

FY2022Q2

FY2022Q1

FY2021

FY2020

FY2019

Por negocioUSD

Nombre

Ganancia

Proporción

Sanofi

1.44B

39.28%

EYLEA

754.30M

20.52%

Bayer

415.00M

11.29%

EYLEA HD

393.20M

10.70%

Libtayo

247.80M

6.74%

Otro

421.70M

11.47%

Sin datos

Por negocio

Por región

Por negocioUSD

Nombre

Ganancia

Proporción

Sanofi

1.44B

39.28%

EYLEA

754.30M

20.52%

Bayer

415.00M

11.29%

EYLEA HD

393.20M

10.70%

Libtayo

247.80M

6.74%

Otro

421.70M

11.47%

Estadísticas de accionistas

Actualizado: sáb., 30 de ago

Accionistas

Tipos de accionistas

Accionistas

Proporción

The Vanguard Group, Inc.

9.07%

BlackRock Institutional Trust Company, N.A.

5.49%

State Street Investment Management (US)

4.68%

Dodge & Cox

3.70%

Fidelity Management & Research Company LLC

3.16%

Otro

73.90%

Accionistas

Proporción

The Vanguard Group, Inc.

9.07%

BlackRock Institutional Trust Company, N.A.

5.49%

State Street Investment Management (US)

4.68%

Dodge & Cox

3.70%

Fidelity Management & Research Company LLC

3.16%

Otro

73.90%

Tipos de accionistas

Accionistas

Proporción

Investment Advisor

48.18%

Investment Advisor/Hedge Fund

28.87%

Hedge Fund

5.39%

Research Firm

2.72%

Pension Fund

2.56%

Bank and Trust

2.16%

Individual Investor

2.02%

Sovereign Wealth Fund

1.23%

Insurance Company

0.08%

Otro

6.77%

Participación institucional



Actualizado: mié., 1 de oct

Periodo del informe

Número de instituciones

Acciones mantenidas

Proporción

Cambio

2025Q3

2594

94.25M

91.26%

-4.09M

2025Q2

2585

99.72M

95.69%

-2.03M

2025Q1

2621

99.84M

93.97%

-1.42M

2024Q4

2581

100.17M

93.15%

-475.65K

2024Q3

2505

99.81M

90.67%

-1.99M

2024Q2

2479

100.87M

93.10%

+570.24K

2024Q1

2440

99.77M

92.44%

+388.23K

2023Q4

2406

98.50M

91.94%

-617.06K

2023Q3

2358

98.79M

92.52%

-1.71M

2023Q2

2360

99.25M

92.00%

-1.42M

Actividad de los accionistas



Nombre

Acciones mantenidas

Proporción

Cambio

Cambio %

Fecha

The Vanguard Group, Inc.

9.37M

9%

+14.55K

+0.16%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

5.67M

5.44%

-75.61K

-1.32%

Jun 30, 2025

State Street Investment Management (US)

4.83M

4.64%

+42.34K

+0.88%

Jun 30, 2025

Dodge & Cox

3.83M

3.67%

+1.50M

+64.64%

Jun 30, 2025

Fidelity Management & Research Company LLC

3.26M

3.13%

-4.14M

-55.90%

Jun 30, 2025

Capital International Investors

3.17M

3.04%

-823.87K

-20.65%

Jun 30, 2025

JP Morgan Asset Management

2.82M

2.7%

-1.26M

-30.95%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.47M

2.37%

-4.53K

-0.18%

Jun 30, 2025

Invesco Capital Management (QQQ Trust)

2.17M

2.09%

-7.70K

-0.35%

Aug 31, 2025

Putnam Investment Management, L.L.C.

2.03M

1.95%

+116.30K

+6.08%

Jun 30, 2025

ETFs relacionados



Actualizado: hace 6 horas

Nombre

Proporción

iShares Biotechnology ETF

5.44%

Amplify Weight Loss Drug & Treatment ETF

4.78%

JPMorgan Healthcare Leaders ETF

2.31%

SPDR S&P Biotech ETF

2.09%

Putnam Focused Large Cap Value ETF

1.57%

Pacer US Cash Cows 100 ETF

1.16%

Health Care Select Sector SPDR Fund

1.14%

JPMorgan Equity Premium Income ETF

0.8%

Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx

0.76%

Indexperts Quality Earnings Focused ETF

0.66%

iShares Biotechnology ETF

Proporción5.44%

Amplify Weight Loss Drug & Treatment ETF

Proporción4.78%

JPMorgan Healthcare Leaders ETF

Proporción2.31%

SPDR S&P Biotech ETF

Proporción2.09%

Putnam Focused Large Cap Value ETF

Proporción1.57%

Pacer US Cash Cows 100 ETF

Proporción1.16%

Health Care Select Sector SPDR Fund

Proporción1.14%

JPMorgan Equity Premium Income ETF

Proporción0.8%

Pacer CFRA-Stovall Equal Weight Seasonal Rot Idx

Proporción0.76%

Indexperts Quality Earnings Focused ETF

Proporción0.66%

Dividendos



Un total de 0.00 USD se ha distribuido en dividendos durante los últimos 5 años.

Fecha

Dividendos

Fecha de registro

Fecha de pago

Fecha ex-dividendo

Feb 04, 2025

REGN.NB Interim Cash Dividend of gross USD 0.88 paid on Mar 20, 2025 going ex on Feb 20, 2025

Feb 20, 2025

Mar 20, 2025

Feb 20, 2025

División de acciones



Fecha

Tipo

Relación

Sin datos

Fecha

Tipo

Relación

Sin datos